Pragmatica-Lung Trial to Mimic "Real-World" Conditions.

Abstract

The phase III randomized Pragmatica-Lung trial, comparing therapies for late-stage or recurrent non-small cell lung cancer, has eased eligibility criteria, simplified primary objectives, and limited data gathering requirements. Investigators hope that the design will speed accrual, expand patient eligibility and diversity, and ease administrative burdens.